K-645 / Kallyope - LARVOL DELTA

A Study of K-645 in the Treatment of Multiple Migraine Attacks (clinicaltrials.gov) - P2 | N=134 | Terminated | Sponsor: Kallyope Inc. | Trial completion date: May 2026 ➔ Nov 2025 | Recruiting ➔ Terminated | Trial primary completion date: May 2026 ➔ Nov 2025; Study stopped for futility based on an interim analysis of efficacy.

Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Migraine • Pain

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Kallyope Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of K-645 in the Treatment of Multiple Migraine Attacks (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: Kallyope Inc.

New P2 trial • CNS Disorders • Migraine • Pain

A First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-645 in Healthy Volunteers (ANZCTR) - P1 | N=16 | Completed | Sponsor: Kallyope, Inc. | Recruiting ➔ Completed

Trial completion • CNS Disorders • Migraine • Pain